论文部分内容阅读
目的观察瑞格列奈联合二甲双胍肠溶片治疗2型糖尿病的临床疗效。方法将60例2型糖尿病患者随机分为3组,A组口服二甲双胍肠溶片250~500mg,3次/d,B组口服瑞格列奈0.5~2mg,3次/d,C组口服二甲双胍肠溶片250~500mg,瑞格列奈0.5~2mg,3次/d,疗程3个月。结果 C组在空腹血糖(FPG),餐后2h血糖(2hPG)及糖化血红蛋白(HbA1c)的控制方面均优于A组和B组(P<0.05)。结论瑞格列奈联合二甲双胍肠溶片治疗2型糖尿病疗效明显,患者依从性好,不良反应少。
Objective To observe the clinical efficacy of repaglinide and metformin enteric-coated tablets in the treatment of type 2 diabetes mellitus. Methods Sixty patients with type 2 diabetes mellitus were randomly divided into three groups: group A was treated with oral metformin 250 mg to 500 mg three times a day, group B received repaglinide 0.5 to 2 mg three times a day, group C was given metformin Enteric-coated tablets 250 ~ 500mg, repaglinide 0.5 ~ 2mg, 3 times / d, course of treatment for 3 months. Results In group C, FPG, 2hPG and HbA1c were better than those in group A and group B (P <0.05). Conclusion The combination of repaglinide and metformin enteric-coated tablets has obvious curative effect on type 2 diabetes patients with good compliance and few adverse reactions.